Clinical Trial Update: Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL [NA]

View source ↗

Summary

A clinical trial is evaluating acute intraocular pressure monitoring after an aflibercept injection (8 mg/0.07 mL) for macular diseases; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Diseases

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | Conditions: Macular Diseases | NA | Status: RECRUITING